Background.—Under the auspices of the College of American Pathologists, the current state
of knowledge regarding pathologic prognostic factors (factors linked to outcome) and …

Objectives: To develop evidence-based guideline recommendations through a systematic
review of the literature to establish standard molecular biomarker testing of colorectal cancer …

Current staging and risk-stratification methods in oncology, while helpful, fail to adequately
predict malignancy aggressiveness and/or response to specific treatment. Increased …

Background The estimation of risk of recurrence for patients with colon carcinoma must be
improved. A robust immune score quantification is needed to introduce immune parameters …

Background Colon cancers with high-frequency microsatellite instability have clinical and
pathological features that distinguish them from microsatellite-stable tumors. We …

Background No treatment options are available for patients with metastatic colorectal cancer
that progresses after all approved standard therapies, but many patients maintain a good …

Purpose Prior reports have indicated that patients with colon cancer who demonstrate high-
level microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have …

Purpose Three agents with differing mechanisms of action are available for treatment of
advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin. In this study, we …

Purpose Fluorouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC)
provides an overall survival of 8 to 12 months. With an increase in surgical resections of …

Background Adjuvant chemotherapy is standard treatment for patients with resected colon
cancer who are at high risk for recurrence, but the efficacy and toxicity of such treatment in …